

## 2025 PORTFOLIO MOMENTUM

- Broadview portfolio companies raised \$285M of funding in 2025
- We are thrilled to have co-invested with top-tier syndicate partners in 2025, including Alexandria Venture Investments, ATHOS, Atlas Venture, BDC Capital, Desjardins Capital, Earlybird Venture Capital, Epidarex Capital, F-Prime Capital, GV, KF Matheson, Lilly Asia Ventures, Lilly, Lumira Ventures, +ND Capital, NEA, Sofinovva Partners, and Vensana Capital
- The pipeline remained robust with more than 700 investment opportunities considered
- Most importantly, Broadview's portfolio companies have touched the lives of more than 800,000 patients to date

## PORTFOLIO MILESTONE HIGHLIGHTS

- **Vectorious** was acquired by Edwards to advance its V-LAP implantable pressure sensor
- **AtaCor** signed a collaboration agreement with Abbott to initiate the pivotal ALARION EV Study evaluating the parasternal EV-ICD system
- **18** companies conducted clinical studies, including **6** pivotal trials
- **Basking Biosciences** received approval by U.S., Canadian, and Australian regulatory bodies to move ahead with Phase 2 proof-of-concept clinical study in stroke patients
- **Cardiosense** received FDA 510(k) clearance for CardioTag for non-invasive ECG, PPG, and SCG measurement

## LONGVIEW VENTURES


Longview Ventures continued a steady pace of investment activity in 2025, focusing on select Broadview clinical-stage opportunities as a complement to Broadview's dedication to Seed and Series A financings.

## 2025 INVESTMENTS


- **HAYA Therapeutics**—\$65M Series A to fund Phase 1a/b study in non-obstructive hypertrophic cardiomyopathy
- **Puzzle Medical**—\$30M Series A-2 to fund feasibility studies and pivotal readiness in patients with ADHD
- **Comanche Bio**—Series B extension closed to fund completion of global Phase 2a study in pregnant preeclampsia patients

**Our mission is to accelerate the development of promising technology for the diagnosis and treatment of cardiovascular disease and stroke through targeted investments.**

**BROADVIEW AND LONGVIEW'S INVESTMENTS ARE LEVERAGED 18.1X BY CO-AND FOLLOW-ON INVESTMENTS AND NON-DILUTIVE GRANT FUNDING**



## BROADVIEW INVESTMENTS BY INDICATION



## TALENT

**Chris Colecchi**, the Founding Managing Director of Broadview, has transitioned to an advisory capacity after 18 years of leading the Broadview and Longview investment team and activities. In a part-time capacity, Chris will continue to support Broadview's efforts, focusing on professional development of the team and further advancement of the Broadview strategy and mission.

**Thomas Needham**, who joined Broadview in 2018, was promoted to Managing Director of Broadview. Tom leads the Biopharmaceuticals practice and oversees Broadview investment strategy and venture portfolio management activities. He also serves as Managing Director of Longview Ventures. Tom has 30 years of experience in venture capital investing, business development, corporate strategy, and C-suite executive management responsibilities in public and private life science companies.

**Daniel Gottlieb**, who joined Broadview in 2019, was promoted to Managing Director of Broadview. Daniel leads the MedTech practice and oversees Broadview investment operations and organizational development. Daniel has spent his career focused on the development and commercialization of treatments for cardiovascular disease, including experience in large multinationals and startup environments across medical devices and biotech.

**Ian Meredith, MBBS, PhD**, joined Broadview's Strategic Advisory Board. Dr. Meredith is currently a Vice Chancellor's Professorial Fellow at Monash University in Melbourne, Australia and a non-executive director serving on the boards of both US and Australian private and public companies. He recently retired as the Executive Vice President and Global Chief Medical Officer at Boston Scientific in 2023.



## BROADVIEW TEAM

### MANAGEMENT

Daniel Gottlieb  
*Managing Director*

Tom Needham  
*Managing Director*

Christopher Colecchi  
*Founding Managing Director*

### INVESTMENT TEAM

Christopher de Souza, PhD  
Benjamin Kreitman  
Hewmun Lau  
David Milan, MD  
Khushbu Modi  
Nichole Neal, MBA  
David Prim, PhD  
Sunny Varshney, MD

### STRATEGIC ADVISORY BOARD

Eugene Braunwald, MD  
Costantino Iadecola, PhD  
Joseph Loscalzo, MD, PhD  
Michael Mendelsohn, MD  
Ian Meredith, MBBS, PhD  
Eric Rose, MD  
Hugh Watkins, MD, PhD

### ADVISORS

Annabel Chen-Tournoux, MD  
Teo Dagi, MD  
Marc Semigran, MD  
Viviany Taqueti, MD, MPH



## LONGVIEW TEAM

### MANAGEMENT

Tom Needham  
*Managing Director*

Christopher de Souza, PhD  
Daniel Gottlieb  
Benjamin Kreitman  
Hewmun Lau  
Khushbu Modi  
Nichole Neal, MBA  
David Prim, PhD  
Sunny Varshney, MD

### INVESTMENT ADVISORY COMMITTEE

#### External Members

Jan Garfinkle  
Terry McGuire  
Chris Mirabelli, PhD  
Eric Rose, MD

#### Leducq Members

Martin Landaluce  
David Milan, MD  
David Tancredi, MD, PhD

# INVESTMENTS THROUGH 2025

Company	Technology/Therapy	Founders/Management
<b>2024</b>		
IsomAb Bio	<i>anti-VEGFA<sub>165</sub>b antibody for the treatment of stable angina</i>	Dave Bates, Philip Brainin, Anker Lundemose
CorFlow	<i>combination diagnostic and drug delivery platform for MVO</i>	Paul Mead, Rob Schwartz, Martin Rothman
Alveron Pharma	<i>reversal agent for intracerebral hemorrhage</i>	Ben Nichols, Stephan Peters
Mosanna Therapeutics	<i>intranasal spray for obstructive sleep apnea</i>	David Weber, Jonathan Talbot, Sascha Oliver Bucher
Relief Cardiovascular	<i>renal vein unloading system for diuretic resistant HF</i>	Alexander Cooper, Brent Ratz, Arshad Quadri
<b>2022</b>		
Puzzle Medical	<i>percutaneous heart pump for patients with advanced HF</i>	Jade Doucet-Martineau, Gabriel Georges, Francois Trudeau
Nyra Medical	<i>transcatheter implant to treat mitral valve regurgitation</i>	Lori Chmura, Murali Padala, Eric Sarin
Cardiosense	<i>noninvasive sensor and algorithms for heart failure management</i>	Eric Meizlish, Omer Inan, Andrew Carek
<b>2021</b>		
XII Medical	<i>minimally-invasive technology to address obstructive sleep apnea</i>	Garrett Schwab, Anthony Caparso
RapidPulse	<i>aspiration system to treat acute ischemic stroke</i>	Sean McBrayer, David Gill, Carlos Rivera
Comanche BioPharma	<i>siRNA therapeutic for the treatment of preeclampsia</i>	T. Scott Johnson, Mike Young, Craig Mello
<b>2020</b>		
Antag Therapeutics	<i>GIPR antagonist for obesity</i>	Joerg Moeller, Alexander Sparre-Ulrich, Jens Juul Holst
Basking Biosciences	<i>reversible anti-vWF aptamer for acute ischemic stroke</i>	Julia Owens, Shahid Nimjee, Bruce Sullenger
HAYA Therapeutics	<i>ncRNA-targeting antifibrotic therapeutics for heart failure</i>	Samir Ounzain, Daniel Blessing
<b>2019</b>		
Alleviant Medical	<i>atrial shunt for the treatment of heart failure</i>	Jacob Kriegel, Adam Berman, Mary Byron
Renovacor*	<i>BAG3 gene therapy for a rare, familial form of dilated cardiomyopathy</i>	Maggie Cook, Arthur Feldman
CroiValve	<i>percutaneously implanted device for tricuspid regurgitation</i>	Lucy O'Keeffe, Martin Quinn
<b>2018</b>		
AtaCor Medical	<i>leadless extravascular pacing and defibrillation systems</i>	Rick Sanghera, Sean McGeehan, Alan Marcovecchio
Kantum Pharma	<i>P2Y14 inhibitor for cardiac surgery-associated acute kidney injury</i>	Sylvie Breton, Glenn Batchelder
<b>2017</b>		
NIDO Surgical*	<i>device for epicardial ablation of ventricular tachycardia</i>	Pedro del Nido, Nikolay Vasilyev, Thomas Marchand
Mellitus	<i>novel biomarker for the screening and diagnosis of gestational diabetes</i>	Jose Halperin, Michael Chorev
Adient	<i>bioresorbable IVC filter for prevention of pulmonary embolism</i>	Mitch Eggers, Joseph Steele
Vectorious*	<i>direct left atrial pressure sensor</i>	Oren Goldshtein, Eyal Orion
EP Sciences	<i>novel defibrillation waveform to reduce pain associated with ICD therapies</i>	Ron Berger, Howard Levin
<b>2016</b>		
FineHeart	<i>fully implantable, miniaturized circulatory support device for HF</i>	Arnaud Mascarell, Stephane Garrigue, Jean-Luc Boulnois
Gila Therapeutics	<i>topical lingual PYY agonist for treatment of obesity</i>	Tom Vasicek, Rich Horan
Aeromics	<i>small molecule for stroke-related cerebral edema</i>	Tom Zindrick, Trevor Thompson
<b>2015</b>		
Pulmokine*	<i>small molecule for pulmonary artery hypertension</i>	Larry Zisman, Shreefal Mehta
Lyra Therapeutics*	<i>bioresorbable platform for multiple indications</i>	Bob Langer, George Whitesides, Maria Palasis
Epirium Bio (Cardero)	<i>mitochondrial biogenesis platform technology</i>	Alexander Casdin, George Schreiner, Sundee Dugar

\* Exited

# INVESTMENTS THROUGH 2025

Company	Technology/Therapy	Founders/Management
<b>2014</b>		
ZZ Biotech	<i>mutant APC peptide therapeutic for stroke</i>	Berislav Zlokovic, Kent Pryor, Joseph Romano
Ischemia Care	<i>immune cell gene expression profile diagnostic for stroke</i>	Jeff June
Acesion Pharma	<i>Small molecule to treat chronic atrial fibrillation</i>	Ulrik Sørensen, Morten Grunnet, Anders Gaarsdal Holst
Aria CV	<i>counterpulsation device for pulmonary hypertension</i>	John Scandurra, Karl Vollmers, Dan Gladney
<b>2013</b>		
Zumbro Discovery	<i>peptide therapeutic for treatment of resistant hypertension</i>	John Burnett, Horng Chen
BioKier	<i>small molecule anti-diabetic treatment</i>	George Szewczyk, Roger Nolan
Remedy*	<i>small molecule for the treatment of central nervous system edema</i>	Sven Jacobson
GI Windows	<i>non-surgical approach to gastric bypass</i>	Chris Thompson, Marvin Ryou
<b>2012</b>		
VGS	<i>external support for saphenous vein grafts in CABG</i>	Eyal Orion
InfoBionic	<i>cloud-based remote monitoring platform for atrial fibrillation</i>	Jeremy Ruskin, Stuart Long
Herantis*	<i>VEGF based gene therapy for lymphedema</i>	Antti Vuolanto
DeclImmune	<i>MAb for treatment of post MI and I/R injury</i>	Christopher Mirabelli, Walter Newman
<b>2011</b>		
Cardialen	<i>implantable cardioversion for the treatment of atrial fibrillation</i>	Igor Efimov, Jeff Peters
NuPulse	<i>counterpulsation device for the treatment of heart failure</i>	Valluvan Jeevanandam, Douglas Altschuler
Aggamin	<i>sFlt-1 apheresis treatment for preeclampsia</i>	Ravi Thadhani, Paul Kussie, Ananth Karumanchi
Provasculon*	<i>peptide therapeutics for treatment of myocardial infarction</i>	Rich Lee, Roger Kitterman
Apama*	<i>novel ablation system for treatment of atrial fibrillation</i>	Amr Salahieh
<b>2010</b>		
Allosteros	<i>CaMKII inhibitors for heart failure and atrial fibrillation</i>	Howard Schulman, Mark Anderson
Intravascular Imaging	<i>NIRF device for intracoronary artery imaging</i>	Farouc Jaffer, Vasilis Ntziachristos
Capricor*	<i>allogeneic stem cell therapy after myocardial infarction</i>	Eduardo and Linda Marbán
CellAegis	<i>remote ischemic conditioning for myocardial infarction</i>	Andrew Redington, Chris Calderone
<b>2009</b>		
CardiAQ Valve*	<i>transcatheter mitral valve</i>	Brent Ratz, Arshad Quadri, Rob Michiels
VentriNova	<i>gene therapy for regeneration of cardiac tissue</i>	Hina Chaudhry
miRagen*	<i>microRNAs for cardiovascular and oncology indications</i>	Bruce Booth, Mike Bristow, Eric Olson

\* Exited